^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Cancer

    Related cancers:
    21h
    Preoperative Low Serum Basophil Levels Predict Poor Prognosis for the Patients with Esophageal Squamous Cell Carcinoma. (PubMed, Ann Thorac Cardiovasc Surg)
    Low preoperative basophil count is an independent adverse prognostic factor in ESCC. As basophil count was not correlated with C-reactive protein, it may provide prognostic value beyond conventional inflammation-based markers and could represent a simple, low-cost biomarker to aid risk stratification in the preoperative setting.
    Journal
    |
    CRP (C-reactive protein)
    1d
    ARES: Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy (clinicaltrials.gov)
    P2, N=84, Recruiting, National Cancer Institute, Naples | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ARID1A (AT-rich interaction domain 1A) • DPYD (Dihydropyrimidine Dehydrogenase)
    |
    HER-2 negative • ARID1A mutation
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • simvastatin
    3d
    Construction of circadian clock signature for tumor microenvironment in predicting survival of esophageal squamous cell carcinoma. (PubMed, Front Immunol)
    This research illustrated the prognostic significance of seven DE-CCGs for ESCC patients based on tumor progression and immune infiltration. And the CST3 may serve as an independent prognostic biomarker and a potential therapeutic target for ESCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    PD-L1 expression
    3d
    A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer (clinicaltrials.gov)
    P2, N=28, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    Keytruda (pembrolizumab) • Focus V (anlotinib)
    3d
    Endeavor-2: A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer (clinicaltrials.gov)
    P=N/A, N=266, Not yet recruiting, University Hospital, Antwerp
    New trial • HEOR
    3d
    Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA (clinicaltrials.gov)
    P2, N=40, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Yidafan (ivonescimab)
    3d
    A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) (clinicaltrials.gov)
    P1, N=67, Recruiting, Merck Sharp & Dohme LLC | N=47 --> 67
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    3d
    Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) (clinicaltrials.gov)
    P1/2, N=13, Completed, Merck Sharp & Dohme LLC | N=304 --> 13
    Enrollment change
    |
    SKB315
    3d
    Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer (clinicaltrials.gov)
    P4, N=22, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    paclitaxel
    3d
    Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence (clinicaltrials.gov)
    P2, N=26, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • cisplatin
    3d
    MMP11 Promotes Immune Escape in Esophageal Carcinoma Cells via the PD-L1/c-MYC Signaling Pathway. (PubMed, Iran J Immunol)
    MMP11 promotes ESCA progression by activating the PD-L1/c-MYC pathway and facilitating immune escape. Targeting MMP11 may enhance immunotherapeutic strategies for ESCA.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • FOXP3 (Forkhead Box P3) • MMP11 (Matrix Metallopeptidase 11)
    |
    PD-L1 expression
    3d
    NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts. (PubMed, Cancer Chemother Pharmacol)
    NFE2L2 rs35652124C > T was identified as an independent predictive genetic factor for Grade 4 neutropenia in esophageal cancer patients treated with DCF chemotherapy.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    cisplatin • docetaxel • 5-fluorouracil